BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16:343-356.e3. [PMID: 28625817 DOI: 10.1016/j.cgh.2017.06.016] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 23.2] [Reference Citation Analysis]
Number Citing Articles
1 Mosli MH, Saadah OI. Metabolic bone disease in children and adolescent patients with ulcerative colitis. J Pediatr (Rio J) 2021;97:242-7. [PMID: 32335076 DOI: 10.1016/j.jped.2020.03.003] [Reference Citation Analysis]
2 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
3 Li H, Lai L, Shen J. Development of a susceptibility gene based novel predictive model for the diagnosis of ulcerative colitis using random forest and artificial neural network. Aging (Albany NY). 2020;12:20471-20482. [PMID: 33099536 DOI: 10.18632/aging.103861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xie F, Zhang H, Zheng C, Shen XF. Costunolide improved dextran sulfate sodium-induced acute ulcerative colitis in mice through NF-κB, STAT1/3, and Akt signaling pathways. Int Immunopharmacol 2020;84:106567. [PMID: 32413737 DOI: 10.1016/j.intimp.2020.106567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
5 Kayal M, Kohler D, Plietz M, Khaitov S, Sylla P, Greenstein A, Dubinsky MC. Early Pouchitis Is Associated With Crohn's Disease-like Pouch Inflammation in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2022:izac012. [PMID: 35188532 DOI: 10.1093/ibd/izac012] [Reference Citation Analysis]
6 Chen L, Yang J, Fang L, Wu W, Feng B, Shi Y, Sun M, Sun X, Liu Z. The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820981210. [PMID: 33425012 DOI: 10.1177/1756284820981210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Omori T, Saruta M, Nagaki A, Arai Y, Ohta A, Kuramoto K, Suzuki Y. Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance. Expert Opin Pharmacother 2021;22:1505-11. [PMID: 33832402 DOI: 10.1080/14656566.2021.1905796] [Reference Citation Analysis]
8 Kariyawasam VC, Mourad FH, Mitrev N, Paramsothy S, Selinger CP, Katelaris PH, Jones B, McDonald C, Barr G, Chapman G, Cowlishaw J, Andrews J, Leong RW. Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1524-32. [PMID: 33731581 DOI: 10.1097/MEG.0000000000002101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol 2018;113:1197-205. [PMID: 29925913 DOI: 10.1038/s41395-018-0144-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
10 Riansuwan W, Limsrivilai J. Current status of IBD and surgery of Crohn's disease in Thailand. Ann Gastroenterol Surg 2021;5:597-603. [PMID: 34585044 DOI: 10.1002/ags3.12470] [Reference Citation Analysis]
11 Li K, Feng C, Chen H, Feng Y, Li J. Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012–2021: A Bibliometric Study. Front Med 2022;9:880553. [DOI: 10.3389/fmed.2022.880553] [Reference Citation Analysis]
12 Bresteau C, Amiot A, Kirchgesner J, de'Angelis N, Lefevre JH, Bouhnik Y, Panis Y, Beaugerie L, Allez M, Brouquet A, Carbonnel F, Meyer A. Chronic pouchitis and Crohn's disease of the pouch after ileal pouch-anal anastomosis: Incidence and risk factors. Dig Liver Dis 2021;53:1128-35. [PMID: 33931341 DOI: 10.1016/j.dld.2021.03.027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225-31. [PMID: 31634390 DOI: 10.1093/ibd/izz247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:6923609. [PMID: 32308714 DOI: 10.1155/2020/6923609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Shi X, Chen Q, Wang F. Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies. Stem Cell Res Ther 2019;10:266. [PMID: 31443677 DOI: 10.1186/s13287-019-1336-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
16 Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Reference Citation Analysis]
17 Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Nachury M, Amiot A. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther 2021. [PMID: 34296456 DOI: 10.1111/apt.16544] [Reference Citation Analysis]
18 Cha JM, Park SH, Rhee KH, Hong SN, Kim YH, Seo SI, Kim KH, Jeong SK, Lee JH, Park SY, Park H, Kim JS, Im JP, Yoon H, Kim SH, Jang J, Kim JH, Suh SO, Kim YK, Ye BD, Yang SK. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 2020;69:1432-40. [PMID: 31822581 DOI: 10.1136/gutjnl-2019-319699] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
19 Worley G, Almoudaris A, Bassett P, Segal J, Akbar A, Ghosh S, Aylin P, Faiz O. Colectomy rates for ulcerative colitis in England 2003-2016. Aliment Pharmacol Ther 2021;53:484-98. [DOI: 10.1111/apt.16202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kayal M, Tixier E, Plietz M, Radcliffe M, Rizvi A, Riggs A, Trivedi P, Khaitov S, Sylla P, Greenstein A, Dubinsky MC, Grinspan A. Clostridioides Difficile Infection Is a Rare Cause of Infectious Pouchitis. Inflamm Intest Dis 2020;5:59-64. [PMID: 32596255 DOI: 10.1159/000505658] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Sieber A, Aberra FN, Bonhomme B, Mckeever L, Lewis JD. Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases. Dig Dis Sci. [DOI: 10.1007/s10620-021-07361-z] [Reference Citation Analysis]
22 Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol 2022;15:175628482210807. [DOI: 10.1177/17562848221080793] [Reference Citation Analysis]
23 Kayal M, Ungaro RC, Colombel JF. The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00335-9. [PMID: 33753242 DOI: 10.1016/j.cgh.2021.03.025] [Reference Citation Analysis]
24 Yoon JY, Cha JM, Lee CK, Park YS, Huh KC, Shin JE, Kim YS, Eun CS, Yoon SM, Cheon JH, Park YS, Ye BD, Lee Y, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID). Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: Results from a hospital-based inception cohort study (MOSAIK). J Gastroenterol Hepatol 2021;36:2149-56. [PMID: 33555067 DOI: 10.1111/jgh.15435] [Reference Citation Analysis]
25 Wang S, Xu M, Huang K, Zhi J, Sun C, Wang K, Zhou Q, Gao L, Jia Q, Shi H, An Z, Li P, Huang W. Biocompatible metal-free organic phosphorescent nanoparticles for efficiently multidrug-resistant bacteria eradication. Sci China Mater 2020;63:316-24. [DOI: 10.1007/s40843-019-1191-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
26 Ma Q, Ouyang Y, Meng F, Noolvi MN, Avvaru SP, More UA, Aminabhavi TM, Du M, Liu H, Zhuang Y, Pang M, Cai T, Cai Y. A review of pharmacological and clinical studies on the application of Shenling Baizhu San in treatment of Ulcerative colitis. Journal of Ethnopharmacology 2019;244:112105. [DOI: 10.1016/j.jep.2019.112105] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
27 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Rodríguez-lago I, Ferreiro-iglesias R, Nos P, Gisbert JP. Manejo de la colitis ulcerosa aguda grave en España: Resultados de una encuesta sobre práctica clínica. Gastroenterología y Hepatología 2019;42:90-101. [DOI: 10.1016/j.gastrohep.2018.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Aguirre-Allende I, Enríquez-Navascués JM, Elorza G, Etxart A, Echeveste A, Borda-Arrizabalaga N, Placer C, Saralegui Y. Care burden and outcome of the surgical management of ulcerative colitis: A retrospective analysis of the last 20 years in a tertiary hospital in Spain. Cir Esp (Engl Ed) 2021:S0009-739X(21)00259-1. [PMID: 34509292 DOI: 10.1016/j.ciresp.2021.08.008] [Reference Citation Analysis]
30 Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, Raine T, Parkes M; UK IBD BioResource Investigators., UK IBD Bioresource Investigators. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut 2021;70:677-86. [PMID: 33004550 DOI: 10.1136/gutjnl-2019-320185] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
31 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
33 Cao Y, Su Q, Zhang B, Shen F, Li S. Efficacy of stem cells therapy for Crohn's fistula: a meta-analysis and systematic review. Stem Cell Res Ther 2021;12:32. [PMID: 33413661 DOI: 10.1186/s13287-020-02095-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
34 Burisch J, Lophaven S, Munkholm P, Langholz E. Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort. Aliment Pharmacol Ther 2021. [PMID: 34713926 DOI: 10.1111/apt.16677] [Reference Citation Analysis]
35 Reinglas J, Restellini S, Gonczi L, Kurti Z, Verdon C, Nene S, Kohen R, Afif W, Bessissow T, Wild G, Seidman E, Bitton A, Lakatos PL. Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. Dig Liver Dis. 2019;51:340-345. [PMID: 30591367 DOI: 10.1016/j.dld.2018.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Hoang CM, Maykel JA, Davids JS, Crawford AS, Sturrock PR, Alavi K. Distribution of Elective Ileal Pouch-Anal Anastomosis Cases for Ulcerative Colitis: a Study Utilizing the University Health System Consortium Database. J Gastrointest Surg 2020;24:2613-9. [DOI: 10.1007/s11605-019-04443-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Agrawal M, Colombel JF. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? Gastrointest Endosc Clin N Am. 2019;29:421-436. [PMID: 31078245 DOI: 10.1016/j.giec.2019.02.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
38 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Liu N, Wang H, Yang Z, Zhao K, Li S, He N. The role of functional oligosaccharides as prebiotics in ulcerative colitis. Food Funct 2022. [PMID: 35703137 DOI: 10.1039/d2fo00546h] [Reference Citation Analysis]
40 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
41 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
42 Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med 2021;10:5642. [PMID: 34884344 DOI: 10.3390/jcm10235642] [Reference Citation Analysis]
43 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Seong G, Song JH, Kim JE, Kim TJ, Kim ER, Hong SN, Chang DK, Kim SH, Ha SY, Kim YH. Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflamm Bowel Dis 2022:izac075. [PMID: 35396998 DOI: 10.1093/ibd/izac075] [Reference Citation Analysis]
45 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 George LA, Cross RK. Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). Gastroenterology Clinics of North America 2020;49:705-16. [DOI: 10.1016/j.gtc.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Gu FL, Huang RS, He XM, Chen NF, Han BX, Deng H. Dendrobium huoshanense Polysaccharides Prevent Inflammatory Response of Ulcerative Colitis Rat through Inhibiting the NF-κB Signaling Pathway. Chem Biodivers 2021;18:e2100130. [PMID: 34080308 DOI: 10.1002/cbdv.202100130] [Reference Citation Analysis]
48 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
49 Worley G, Nordenvall C, Askari A, Pinkney T, Burns E, Akbar A, Olén O, Ekbom A, Bottai M, Myrelid P, Faiz O. Restorative surgery after colectomy for ulcerative colitis in England and Sweden: observations from a comparison of nationwide cohorts. Colorectal Dis 2018;20:804-12. [PMID: 29603863 DOI: 10.1111/codi.14113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
50 Ray G. Long-term maintenance treatment of ulcerative colitis in eastern India: a 15-year follow-up. Trop Doct 2018;48:207-13. [DOI: 10.1177/0049475518765291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Rev Gastroenterol Hepatol 2019;13:547-55. [PMID: 31007098 DOI: 10.1080/17474124.2019.1605291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis 2021;15:1184-96. [PMID: 33433562 DOI: 10.1093/ecco-jcc/jjab010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 D'Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis 2021:jjab063. [PMID: 33822915 DOI: 10.1093/ecco-jcc/jjab063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Aoun R, Hanauer S. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2022;16:411-23. [PMID: 35400292 DOI: 10.1080/17474124.2022.2065258] [Reference Citation Analysis]
56 Hou S, Yang X, Tong Y, Yang Y, Chen Q, Wan B, Wei R, Wang Y, Zhang Y, Kong B, Huang J, Chen Y, Lu T, Hu Q, Du D. Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis. Eur J Med Chem 2021;211:113114. [PMID: 33360793 DOI: 10.1016/j.ejmech.2020.113114] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Palasik BN, Wang H. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. J Pharm Pract 2020;:897190020953019. [PMID: 32873116 DOI: 10.1177/0897190020953019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Ogino H, Morikubo H, Fukaura K, Okui T, Gardiner S, Sugiyama N, Yoshii N, Kawaguchi T, Chen H, Nonnenmacher E, Setoguchi S, Nakashima N, Kobayashi T. Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan. J Gastroenterol Hepatol 2021. [PMID: 34738649 DOI: 10.1111/jgh.15732] [Reference Citation Analysis]
59 Peyrin-biroulet L, Lopez A, Cummings JRF, Dignass A, Detlie TE, Danese S. Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Aliment Pharmacol Ther 2018;48:610-7. [DOI: 10.1111/apt.14922] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
60 Laurain P, Guillo L, D’amico F, Netter P, Danese S, Baumann C, Luc A, Clerc-urmes I, Sofos S, Peyrin-biroulet L. Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. Clinical Gastroenterology and Hepatology 2021;19:1899-1905.e1. [DOI: 10.1016/j.cgh.2021.01.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Ma C, Panaccione NR, Nguyen TM, Guizzetti L, Parker CE, Hussein IM, Vande Casteele N, Khanna R, Dulai PS, Singh S, Feagan BG, Jairath V. Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis 2019;13:1201-16. [PMID: 31111881 DOI: 10.1093/ecco-jcc/jjz087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
62 Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35:380-389. [PMID: 31596960 DOI: 10.1111/jgh.14872] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
63 Chen P, Li Y, Zhang X, Zhang Y. Systematic review with meta-analysis: effectiveness of hyperbaric oxygenation therapy for ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211023394. [PMID: 34349835 DOI: 10.1177/17562848211023394] [Reference Citation Analysis]
64 Rönnblom A, Karlbom U. Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort. Scand J Gastroenterol 2021;56:403-9. [PMID: 33577739 DOI: 10.1080/00365521.2021.1882553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Elkharsawi A, Arnim UV, Schmelz R, Sander C, Stallmach A, Teich N, Walldorf J, Reuken PA. SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease. Z Gastroenterol 2022;60:77-80. [PMID: 35042256 DOI: 10.1055/a-1710-3861] [Reference Citation Analysis]
67 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Nag A, Romero B. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease. Health Qual Life Outcomes 2022;20:75. [PMID: 35525935 DOI: 10.1186/s12955-022-01975-1] [Reference Citation Analysis]
69 Burke KE, Ananthakrishnan AN. Tofacitinib: A Jak of All Trades. Clin Gastroenterol Hepatol 2019;17:1438-40. [PMID: 30625401 DOI: 10.1016/j.cgh.2018.12.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
70 Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol 2020;18:2179-2191.e6. [PMID: 31945470 DOI: 10.1016/j.cgh.2020.01.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
71 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
72 Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:748-64. [PMID: 30576644 DOI: 10.1053/j.gastro.2018.12.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
73 Aniwan S, Limsrivilai J, Pongprasobchai S, Pausawasdi N, Prueksapanich P, Kongtub N, Rerknimitr R. Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018. Intest Res 2021;19:186-93. [PMID: 32806871 DOI: 10.5217/ir.2020.00028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
74 Otagiri S, Ohnishi S, Ohara M, Fu Q, Yamamoto K, Yamamoto K, Katsurada T, Sakamoto N. Oleoylethanolamide Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats. Front Pharmacol 2020;11:1277. [PMID: 32922296 DOI: 10.3389/fphar.2020.01277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 33.5] [Reference Citation Analysis]
76 Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol 2022;9:e000853. [DOI: 10.1136/bmjgast-2021-000853] [Reference Citation Analysis]
77 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Pugliese D, Armuzzi A. Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis. United European Gastroenterol J 2020;8:11-2. [PMID: 32213049 DOI: 10.1177/2050640619900575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
79 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis 2021;15:950-9. [PMID: 33475734 DOI: 10.1093/ecco-jcc/jjab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
82 Kayal M, Plietz M, Rizvi A, Radcliffe M, Riggs A, Yzet C, Tixier E, Trivedi P, Ungaro RC, Khaitov S, Sylla P, Greenstein A, Frederic Colombel J, Dubinsky MC. Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients. Inflamm Bowel Dis 2020;26:1079-86. [PMID: 31587035 DOI: 10.1093/ibd/izz227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
83 Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol 2021;14:343-51. [PMID: 34511961 DOI: 10.2147/CEG.S237653] [Reference Citation Analysis]
84 Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G, Sultan K, Lukin D, Dubinsky MC, Colombel JF; New York Crohn’s and Colitis Organization (NYCCO). Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00571-1. [PMID: 34033922 DOI: 10.1016/j.cgh.2021.05.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ananthakrishnan AN. Making sense of clinical predictors. J Gastroenterol Hepatol 2018;33 Suppl 3:7-8. [PMID: 30187548 DOI: 10.1111/jgh.14417] [Reference Citation Analysis]
86 Chen Z, Shen X, Zhou Q, Zhan Q, Xu X, Chen Q, An F, Sun J. Dietary xylo-oligosaccharide ameliorates colonic mucus microbiota penetration with restored autophagy in interleukin-10 gene-deficient mice. JPEN J Parenter Enteral Nutr 2021. [PMID: 34618377 DOI: 10.1002/jpen.2274] [Reference Citation Analysis]
87 Atia O, Orlanski-Meyer E, Lujan R, Ledderman N, Greenfeld S, Kariv R, Daher S, Yanai H, Loewenberg Weisband Y, Gabay H, Matz E, Nevo D, Ollech J, Zittan E, Israeli E, Schwartz D, Chowers Y, Dotan I, Turner D. Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN. J Crohns Colitis 2021:jjab210. [PMID: 34904163 DOI: 10.1093/ecco-jcc/jjab210] [Reference Citation Analysis]
88 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Reference Citation Analysis]
89 Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00331-9] [Reference Citation Analysis]
90 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
91 Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)., Working panel., Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00137-2. [PMID: 35184989 DOI: 10.1016/j.dld.2022.01.127] [Reference Citation Analysis]
92 Yan ZX, Liu YM, Ma T, Xu MJ, Zhang XB, Zha XJ, Yang JH, Jiang P, Chen X, Lin ZW, Wu YH, Zu RZ, Lin WR, Lin XY. Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis: A meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2021;42:101278. [PMID: 33276227 DOI: 10.1016/j.ctcp.2020.101278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Pilon D, Ding Z, Muser E, Obando C, Voelker J, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin 2020;36:1285-94. [PMID: 32427006 DOI: 10.1080/03007995.2020.1771293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Louis E. Do We Still Need Predictors of Disease Severity When Applying a Treat-to-Target Approach in Inflammatory Bowel Disease? J Crohns Colitis 2019;13:399-400. [PMID: 30388196 DOI: 10.1093/ecco-jcc/jjy182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
96 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
97 Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep 2021;11:16440. [PMID: 34385588 DOI: 10.1038/s41598-021-96019-x] [Reference Citation Analysis]
98 Deissler H, Krammer H, Gillessen A. pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). Biomed Rep 2021;15:96. [PMID: 34631051 DOI: 10.3892/br.2021.1472] [Reference Citation Analysis]
99 Mosli M, Alfaer S, Almalaki T, Albeshry A, Aljehani S, Alshmrani B, Habib Z, Jawa H, Qari Y. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes? Eur J Gastroenterol Hepatol 2019;31:80-5. [PMID: 30199472 DOI: 10.1097/MEG.0000000000001249] [Reference Citation Analysis]
100 Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res 2021;19:323-31. [PMID: 32806875 DOI: 10.5217/ir.2020.00039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Sheng K, He S, Sun M, Zhang G, Kong X, Wang J, Wang Y. Synbiotic supplementation containing Bifidobacterium infantis and xylooligosaccharides alleviates dextran sulfate sodium-induced ulcerative colitis. Food Funct 2020;11:3964-74. [DOI: 10.1039/d0fo00518e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
102 Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 2018;3:742-53. [PMID: 30122356 DOI: 10.1016/S2468-1253(18)30231-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
103 Koliani-Pace JL, Siegel CA. Prognosticating the Course of Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2019;29:395-404. [PMID: 31078243 DOI: 10.1016/j.giec.2019.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
104 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
105 Jia X, Guo R, Hu Z, Liu J, Liu J, Li B, Yang Q, He J. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis. Medicine (Baltimore) 2020;99:e22894. [PMID: 33126341 DOI: 10.1097/MD.0000000000022894] [Reference Citation Analysis]
106 Rodríguez C, Elosua A, Prieto C, Pérez E, Irisarri R, Campillo A, Rubio S, Nantes Ó, Angós R, Zozaya JM. Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort. Gastroenterol Hepatol 2021:S0210-5705(21)00003-0. [PMID: 33545242 DOI: 10.1016/j.gastrohep.2020.11.016] [Reference Citation Analysis]
107 Shaffer SR, Rubin DT. Response to Tetangco and Hanauer. Am J Gastroenterol 2021;116:1959-60. [PMID: 34101668 DOI: 10.14309/ajg.0000000000001330] [Reference Citation Analysis]
108 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Kayal M, Saha A, Poojary P, Paramsothy S, Hirten R, Cohen L, Gallinger Z, Mehandru S, Cho J, Greenstein A, Nadkarni G, Dubinsky MC, Colombel JF, Cohen B, Ungaro R. Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. Int J Colorectal Dis 2019;34:1771-9. [PMID: 31512019 DOI: 10.1007/s00384-019-03375-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
110 Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, Batachari LE, Malfavon M, Zhu Q, Weldon K, Humphrey G, Carrillo-Terrazas M, Goldasich LD, Bryant M, Raffatellu M, Quinn RA, Gewirtz AT, Chassaing B, Chu H, Sandborn WJ, Dorrestein PC, Knight R, Gonzalez DJ. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol 2022. [PMID: 35087228 DOI: 10.1038/s41564-021-01050-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
111 Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-rousseau C, Brinar M, Čuković-čavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D’incà R, Salupere R, Chetcuti Zammit S, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P; Epi-IBD Group. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study. Journal of Crohn's and Colitis 2019;13:198-208. [DOI: 10.1093/ecco-jcc/jjy154] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
112 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
113 Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:769-808.e29. [PMID: 30576642 DOI: 10.1053/j.gastro.2018.12.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
114 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
115 Chen J, Jayachandran M, Zhang W, Chen L, Du B, Yu Z, Xu B. Dietary Supplementation with Sea Bass (Lateolabrax maculatus) Ameliorates Ulcerative Colitis and Inflammation in Macrophages through Inhibiting Toll-Like Receptor 4-Linked Pathways. Int J Mol Sci 2019;20:E2907. [PMID: 31207873 DOI: 10.3390/ijms20122907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
116 Schoepfer AM, Tran VDC, Rossel J, Sokollik C, Spalinger J, Safroneeva E, von Graffenried T, Godat S, Hahnloser D, Vavricka SR, Braegger C, Nydegger A; on behalf of the Swiss IBD Cohort Study Group. Impact of Diagnostic Delay on Disease Course in Pediatric- versus Adult-Onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort. Inflamm Intest Dis. [DOI: 10.1159/000520995] [Reference Citation Analysis]
117 de Campos Silva EF, Baima JP, de Barros JR, Tanni SE, Schreck T, Saad-Hossne R, Sassaki LY. Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study. Medicine (Baltimore) 2020;99:e21686. [PMID: 32769938 DOI: 10.1097/MD.0000000000021686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr 2021;9:634739. [PMID: 33681110 DOI: 10.3389/fped.2021.634739] [Reference Citation Analysis]
119 Kayal M, Plietz M, Wang YHW, Khaitov S, Sylla P, Dubinsky MC, Greenstein AJ. Crohn's Disease Like Pouch Inflammation Is Associated With Decreased Odds of Secondary Ileostomy Closure After Ileal Pouch Anal Anastomosis. Inflamm Bowel Dis 2021:izab289. [PMID: 34788818 DOI: 10.1093/ibd/izab289] [Reference Citation Analysis]
120 Lu J, Wang Z, Maimaiti M, Hui W, Abudourexiti A, Gao F. Identification of diagnostic signatures in ulcerative colitis patients via bioinformatic analysis integrated with machine learning. Hum Cell 2021. [PMID: 34731452 DOI: 10.1007/s13577-021-00641-w] [Reference Citation Analysis]
121 Saiki JP, Andreasson JO, Grimes KV, Frumkin LR, Sanjines E, Davidson MG, Park KT, Limketkai B. Treatment-refractory ulcerative colitis responsive to indigo naturalis. BMJ Open Gastroenterol 2021;8:e000813. [PMID: 34969665 DOI: 10.1136/bmjgast-2021-000813] [Reference Citation Analysis]
122 Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020;18:14-23. [PMID: 31301452 DOI: 10.1016/j.cgh.2019.07.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
123 Lu PD, Yuan MC, Quan XP, Chen JF, Zhao YH. Preclinical studies of licorice in ulcerative colitis: A systematic review with meta-analysis and network pharmacology. J Ethnopharmacol 2022;:115444. [PMID: 35671864 DOI: 10.1016/j.jep.2022.115444] [Reference Citation Analysis]
124 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 33.5] [Reference Citation Analysis]
125 O'Hagan P, Limdi J, Akbar A, Tucknott S, Kahol DN. Ulcerative colitis: understanding the impact of ulcerative colitis on everyday life and exploring the unmet needs of patients. Curr Med Res Opin 2021;37:1901-11. [PMID: 34420463 DOI: 10.1080/03007995.2021.1971180] [Reference Citation Analysis]
126 Takagi T, Uchiyama K, Kajiwara-Kubota M, Kashiwagi S, Toyokawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Yoshida N, Kamada K, Ishikawa T, Konishi H, Kishimoto M, Yagi N, Naito Y, Itoh Y. The efficacy of linked color imaging for the endoscopic diagnosis of mucosal healing in quiescent ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 33710655 DOI: 10.1111/jgh.15489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol 2021;:1-8. [PMID: 34932423 DOI: 10.1080/00365521.2021.2015801] [Reference Citation Analysis]
128 Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Lair-mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease 2020;52:268-73. [DOI: 10.1016/j.dld.2019.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
130 Wei M, Li H, Li Q, Qiao Y, Ma Q, Xie R, Wang R, Liu Y, Wei C, Li B, Zheng C, Sun B, Yu B. Based on Network Pharmacology to Explore the Molecular Targets and Mechanisms of Gegen Qinlian Decoction for the Treatment of Ulcerative Colitis. Biomed Res Int 2020;2020:5217405. [PMID: 33299870 DOI: 10.1155/2020/5217405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, de Santos CR, Carpio D. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain. Patient Prefer Adherence 2018;12:1815-23. [PMID: 30271125 DOI: 10.2147/PPA.S175026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
132 Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021;160:1452-1460.e21. [PMID: 33421515 DOI: 10.1053/j.gastro.2020.10.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
133 Zeng J, Wang Z, Yang X. Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03312-3] [Reference Citation Analysis]
134 Dulai PS, Jairath V. How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? Clin Gastroenterol Hepatol. 2020;18:1300-1308. [PMID: 31887449 DOI: 10.1016/j.cgh.2019.12.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
135 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
136 Vuyyuru SK, Kedia S, Kalaivani M, Sahu P, Kante B, Kumar P, Ranjan MK, Makharia G, Ananthakrishnan A, Ahuja V. Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. Future Microbiol 2021;16:1215-27. [PMID: 34590904 DOI: 10.2217/fmb-2020-0242] [Reference Citation Analysis]
137 Dulai PS, Sandborn WJ, Murphy J. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1170-1179.e10. [PMID: 32437872 DOI: 10.1016/j.cgh.2020.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Ni A, Al-Qahtani M, Salama E, Marinescu D, Khalil MA, Faria J, Morin N, Ghitulescu G, Vasilevsky CA, Boutros M. Trends in Colectomies for Colorectal Neoplasms in Ulcerative Colitis: a National Inpatient Sample Database Analysis over Two Decades. J Gastrointest Surg 2020;24:1721-8. [PMID: 32557016 DOI: 10.1007/s11605-020-04666-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
140 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Reference Citation Analysis]
141 Swaminathan A, Fan D, Borichevsky GM, Mules TC, Hirschfeld E, Frampton CM, Day AS, Siegel CA, Gearry RB. The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course. Aliment Pharmacol Ther 2022. [PMID: 35633043 DOI: 10.1111/apt.17058] [Reference Citation Analysis]
142 Yan X, Lu QG, Zeng L, Li XH, Liu Y, Du XF, Bai GM. Synergistic protection of astragalus polysaccharides and matrine against ulcerative colitis and associated lung injury in rats. World J Gastroenterol 2020; 26(1): 55-69 [PMID: 31933514 DOI: 10.3748/wjg.v26.i1.55] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
143 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
144 Yau YY, Wasinger VC, Hirten RP, Chuang E, Huntsman M, Stylli J, Shimizu J, Yajnik V, Smith J, Lee SN, Singh S, Wahl C, Leong RW, Sands BE. Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflamm Bowel Dis 2021;27:S17-24. [PMID: 34791290 DOI: 10.1093/ibd/izab179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Kayal M, Lambin T, Plietz M, Rizvi A, Radcliffe M, Khaitov S, Sylla P, Greenstein AJ, Colombel JF, Dubinsky MC, Ungaro RC. Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure. Clin Gastroenterol Hepatol 2021;19:1491-1493.e3. [PMID: 32668342 DOI: 10.1016/j.cgh.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Dalal RS, Ananthakrishnan AN, Hamilton MJ, Winter RW. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Dig Dis Sci 2021;66:733-7. [PMID: 33569666 DOI: 10.1007/s10620-021-06852-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis 2019;25:1854-61. [PMID: 31050734 DOI: 10.1093/ibd/izz071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]